Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation

作者
Yaara Yerushalmi,Noga Shem‐Tov,Ivetta Danylesko,Jonathan Canaani,Abraham Avigdor,Ronit Yerushalmi,Arnon Nagler,Avichai Shimoni
出处
期刊:Haematologica [Ferrata Storti Foundation]
卷期号:108 (7): 1782-1792 被引量:33
标识
DOI:10.3324/haematol.2022.281877
摘要

Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) relapsing after a first transplant (HSCT1). However, patients allocated to HSCT2 may be a selected group with better prognosis and the added efficacy of HSCT2 is not well established. We retrospectively analyzed 407 consecutive patients with relapsed AML/MDS after HSCT1. Sixty-two patients had HSCT2 (15%) and 345 did not. The 2-year cumulative incidence rates of non-relapse mortality and relapse after HSCT2 were 26% (95% confidence interval [95% CI]: 17-39%) and 50% (95% CI: 39-65%), respectively. The 5-year overall survival rates were 25% (95% CI: 14-36%) and 7% (95% CI: 4-10%) in the HSCT2 and no-HSCT2 groups, respectively. Multivariate analysis identified female gender (hazard ratio [HR]=0.31, P=0.001), short remission duration after HSCT1 (HR=2.31, P=0.05), acute graft-versus-host disease after HSCT1 (HR=2.27, P=0.035), HSCT2 from a haplo-identical donor (HR=13.4, P=0.001) or matched unrelated donor (HR=4.53, P=0.007) and relapse after HSCT1 in earlier years (HR=2.46, P=0.02) as factors predicting overall survival after HSCT2. Multivariate analysis of all patients including HSCT2 as a timedependent variable identified relapse within 6 months after HSCT1 (HR=2.32, P<0.001), acute graft-versus-host disease before relapse (HR=1.47, P=0.005), myeloablative conditioning in HSCT1 (HR=0.67, P=0.011), female gender (HR=0.71, P=0.007), relapse in earlier years (HR=1.33, P=0.031) and not having HSCT2 (HR=1.66, P=0.010) as predictive of overall survival after relapse. In conclusion, HSCT2 is associated with longer survival compared to non-transplant treatments and may be the preferred approach in a subset of patients with relapsed AML/MDS after HSCT1.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cy8971完成签到,获得积分10
刚刚
1秒前
NL发布了新的文献求助30
1秒前
Tqun完成签到,获得积分10
2秒前
yy完成签到,获得积分10
2秒前
成林完成签到,获得积分10
2秒前
xiaoxiao完成签到,获得积分10
3秒前
现实的一天完成签到,获得积分10
3秒前
4秒前
iitj发布了新的文献求助10
5秒前
余香的应助被yy采纳,获得10
5秒前
yuchuncheng完成签到,获得积分0
6秒前
gycao2025发布了新的文献求助10
6秒前
lzl007完成签到 ,获得积分0
8秒前
8秒前
Yolo完成签到 ,获得积分20
10秒前
特特特特特完成签到,获得积分10
10秒前
哈基米这一块完成签到,获得积分10
10秒前
Fly完成签到,获得积分10
10秒前
10秒前
胡杨树2006完成签到,获得积分10
11秒前
Fan完成签到 ,获得积分0
11秒前
椰子云的应助被邢一采纳,获得10
11秒前
冷cool完成签到,获得积分10
12秒前
Lucas完成签到,获得积分10
12秒前
12秒前
12秒前
dd完成签到,获得积分10
12秒前
毛啊毛完成签到,获得积分10
14秒前
14秒前
森林木发布了新的文献求助10
14秒前
qhebdb完成签到 ,获得积分10
15秒前
米豆完成签到 ,获得积分10
16秒前
123456qqqq发布了新的文献求助50
16秒前
dd发布了新的文献求助10
16秒前
16秒前
锦诗完成签到,获得积分10
17秒前
贪玩的水壶完成签到 ,获得积分10
17秒前
762323661完成签到,获得积分10
17秒前
wtian1221完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159151
求助须知:如何正确求助?哪些是违规求助? 9554617
关于积分的说明 21719982
捐赠科研通 7748814
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552091
邀请新用户注册赠送积分活动 2471436